Seattle Genetics Makes Case for Expanded Use of Adcetris as Lymphoma Maintenance Therapy

Updated with new information.

SAN FRANCISCO (TheStreet) -- The use of Seattle Genetics' (SGEN) Adcetris as a maintenance therapy after a stem-cell transplant in "high risk" Hodgkin lymphoma patients led to a 20 percentage point improvement in relapse rates compared to a placebo after two years of follow-up, researchers reported Saturday.

The new Adcetris data comes from a phase III study known as AETHERA, which is being presented in full at the American Society of Hematology annual meeting underway here. Next year, Seattle Genetics intends to seek approval from regulators to expand the use of Adcetris into a larger pool of Hodgkin lymphoma patients based on the AETHERA study results.

Must Read: Jim Cramers 4 Best Stock Picks for the Health Care Sector

See more here:
Seattle Genetics Makes Case for Expanded Use of Adcetris as Lymphoma Maintenance Therapy